24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

NCT02347072 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD

Interventions

DRUG: GFF MDI (PT003)
DRUG: Placebo MDI
DRUG: Spiriva® Respimat® (Tiotropium Bromide)

Sponsor

Pearl Therapeutics, Inc.